Dr. Luggen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
311 Straight St
Cincinnati, OH 45219Phone+1 513-559-2898Fax+1 513-475-5415
Education & Training
University of Cincinnati Medical Center/College of MedicineFellowship, Allergy and Immunology, 1980 - 1982- University of Cincinnati Medical Center/College of MedicineResidency, Internal Medicine, 1974 - 1977
Columbia University Vagelos College of Physicians and SurgeonsClass of 1974
Certifications & Licensure
OH State Medical License 1977 - 2026- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2002-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Top MD Consumers Checkbook
- Join now to see all
Clinical Trials
- Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis Start of enrollment: 2012 Jun 01
- Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis Start of enrollment: 2015 Feb 21
Publications & Presentations
PubMed
- 82 citationsA controlled trial comparing sulfasalazine, gold sodium thiomalate, and placebo in rheumatoid arthritis.Williams Hj, John R. Ward, Stephen L. Dahl, Daniel O. Clegg, Robert F. Willkens
Arthritis and Rheumatism. 1988-06-01 - 162 citationsComparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A department of veterans affairs cooperative studyDaniel O. Clegg, Domenic J. Reda, M Weisman, Warren D. Blackburn, John J. Cush
Arthritis and Rheumatism. 1996-12-01 - 51 citationsLongterm Safety and Efficacy of Abatacept Through 5 Years of Treatment in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibi...Mark C. Genovese, Michael Schiff, Michael E. Luggen, Manuela Le Bars, Richard Aranda
The Journal of Rheumatology. 2012-08-01
Press Mentions
R-pharm’s Rheumatoid Arthritis Drug, Olokizumab, Offers Significant Benefits in Phase 3 CREDO TrialMay 20th, 2021
Grant Support
- Sulfasalazine In The Treatment Of Ankylosing SpondylitisNational Center For Research Resources1990
- Early Undifferentiated Connective Tissue DiseaseNational Center For Research Resources1990
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
